TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6684153

Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fish protein (cod fish)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Mixed protein (50:50 mixture of SPI and fish protein)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI) relative to fish protein
Number of subjects: 21
Study: 31431412

Group type: EXPERIMENTAL
Intervention: HBsAg/CpG 1018 (HEPLISAV-B®)
Number of subjects: 480
Study: 28244291

Group type: EXPERIMENTAL
Intervention: Idarubicin (10 mg/m²/week) as part of a reinduction regimen including prednisolone, vincristine, and L-asparaginase.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Idarubicin (10 mg/m²/week) as part of a reinduction regimen.
Number of subjects: 44
Study: 24659208

Group type: EXPERIMENTAL
Intervention: Combined soy foods group (soy protein and whole soy)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo group (milk placebo)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Combined isoflavone group (isoflavone and daidzein)
Number of subjects: 450
Study: 24405687

Group type: EXPERIMENTAL
Intervention: RBC transfusion
Number of subjects: 521

Group type: COMPARATOR
Intervention: Non-intervention
Number of subjects: 521
Study: 22943372

Group type: EXPERIMENTAL
Intervention: Determinants of LBW
Number of subjects: 14040

Group type: EXPERIMENTAL
Intervention: Determinants of SGA
Number of subjects: 14040

Group type: EXPERIMENTAL
Intervention: Determinants of preterm birth
Number of subjects: 14040

Group type: EXPERIMENTAL
Intervention: Preventable determinants
Number of subjects: 14040
Study: 19542853

Group type: EXPERIMENTAL
Intervention: Low pressure pneumoperitoneum (8 mm Hg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: High pressure pneumoperitoneum (12 mm Hg)
Number of subjects: 26
Study: 17692448

Group type: EXPERIMENTAL
Intervention: Amisulpride (458.3 mg/day)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Risperidone (4.2 mg/day)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 87

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 87
Study: 15505596

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (1200 mg/d)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 11120490

Group type: EXPERIMENTAL
Intervention: Validated patient information leaflet (PIL) on oral cancer
Number of subjects: 800
Study: 9888161

Group type: EXPERIMENTAL
Intervention: Muscle biopsy examination
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Immunolabelling for desmin
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Immunolabelling for dystrophin, actin, and myosin heavy chains
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Myosin ATPase activity
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Electron microscopy
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Immunolabelling for cathepsin B, lysozyme, and ubiquitin
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Immunolabelling for heat shock protein 72
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: APACHE II scores
Number of subjects: 57
Study: 7625194

Group type: EXPERIMENTAL
Intervention: Moclobemide (378 mg +/‐ 76 mg/day)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Fluoxetine (36 mg +/‐ 8 mg/day)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both drug groups
Number of subjects: 59
Study: 2684489

Group type: EXPERIMENTAL
Intervention: Health‐Net (treatment group)
Number of subjects: 1003
Study: 725

Group type: EXPERIMENTAL
Intervention: psychotherapy with Ro 5‐3350 (TH/Ro)
Number of subjects: 78

Group type: COMPARATOR
Intervention: psychotherapy with placebo (TH/P)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Ro 5‐3350 without psychotherapy (NIH/Ro)
Number of subjects: 78

Group type: COMPARATOR
Intervention: placebo without psychotherapy (NTH/P)
Number of subjects: 78
Study: 31238370

Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation (PPV)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Sustained inflation (SI)
Number of subjects: 44
Study: 28102113

Group type: EXPERIMENTAL
Intervention: High-intensity RAGT at 70% of HRR
Number of subjects: 34

Group type: COMPARATOR
Intervention: High-intensity RAGT at RPE of 15
Number of subjects: 34
Study: 26939318

Group type: EXPERIMENTAL
Intervention: Fire-needle treatment (once every two days for 30 days, 15 times total)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fire-needle treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rehabilitation exercises (five times a week for 4 weeks, 20 times total)
Number of subjects: 60
Study: 23112286

Group type: EXPERIMENTAL
Intervention: Novel neonatal resuscitation cart (NRC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Generic code cart (GCC)
Number of subjects: 15
Study: 21835288

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: hsTnI
Number of subjects: 318

Group type: COMPARATOR
Intervention: cTnT
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Unbound free fatty acids (FFAu)
Number of subjects: 318

Group type: COMPARATOR
Intervention: cTnT with NT-proBNP
Number of subjects: 318

Group type: COMPARATOR
Intervention: cTnT with hsTnI
Number of subjects: 318

Group type: COMPARATOR
Intervention: cTnT with FFAu
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: hsTnI with FFAu
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: FFAu in serial sampling
Number of subjects: 318
Study: 19747247

Group type: EXPERIMENTAL
Intervention: Methylaminolevulinate (MAL) 160 mg/g cream
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (ALA) cream 20%
Number of subjects: 34
Study: 16675905

Group type: EXPERIMENTAL
Intervention: Temocapril (1 mg daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 24
Study: 15606398

Group type: EXPERIMENTAL
Intervention: Mesalazine micropellets (3 g/day)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Mesalazine tablets (3 g/day)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Both treatments (micropellets and tablets)
Number of subjects: 362
Study: 11748520

Group type: COMPARATOR
Intervention: Nitroglycerin (2 microg/kg/min infusion)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Milrinone (50 microg/kg loading dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Combination of nitroglycerin and milrinone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Phenylephrine (administered to increase mean arterial pressure by 20%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Phenylephrine with milrinone or both drugs combined
Number of subjects: 30
Study: 9426799

Group type: EXPERIMENTAL
Intervention: Active smokers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abstinent smokers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 0
Study: 8491393

Group type: EXPERIMENTAL
Intervention: Loperamide‐N‐oxide (3 mg orally twice daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3046883

Group type: EXPERIMENTAL
Intervention: Cicletanine 12.5 mg daily
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Cicletanine 25 mg daily
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Cicletanine 50 mg daily
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Cicletanine 100 mg daily
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Cicletanine 200 mg daily
Number of subjects: 125

Group type: COMPARATOR
Intervention: Cicletanine 50 mg daily (12 weeks)
Number of subjects: 125
Study: 30350153

Group type: EXPERIMENTAL
Intervention: JD (passive simulated jogging device)
Number of subjects: 22

Group type: COMPARATOR
Intervention: SHAM control
Number of subjects: 22
Study: 28471012

Group type: COMPARATOR
Intervention: Transvenous lead placement
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Epicardial lead placement
Number of subjects: 52
Study: 25380167

Group type: EXPERIMENTAL
Intervention: Multielectrode renal denervation (RDN)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 24103531

Group type: EXPERIMENTAL
Intervention: Veress needle (VER)
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Direct trocar insertion (DIR)
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Open technique (OP)
Number of subjects: 595
Study: 22082432

Group type: EXPERIMENTAL
Intervention: Acupressure at the Sanyinjiao point
Number of subjects: 86

Group type: COMPARATOR
Intervention: Sham pressure
Number of subjects: 86
Study: 18450322

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus conventional-dose epirubicin (GE)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GC)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patients with expression of both ERCC1 and TopoIIalpha
Number of subjects: 80
Study: 21617335

Group type: EXPERIMENTAL
Intervention: CDC web-based intervention (screen for life)
Number of subjects: 1224

Group type: EXPERIMENTAL
Intervention: Tailored interactive computer-based intervention
Number of subjects: 1224

Group type: COMPARATOR
Intervention: Survey-only control group
Number of subjects: 1224
Study: 16059842

Group type: EXPERIMENTAL
Intervention: Computerized version of the WILDE intelligence test (WIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paper-and-pencil version of the WILDE intelligence test (WIT)
Number of subjects: 0
Study: 11833826

Group type: EXPERIMENTAL
Intervention: Lovastatin ER 40 mg
Number of subjects: 76

Group type: COMPARATOR
Intervention: Lovastatin IR 40 mg
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Lovastatin ER
Number of subjects: 76

Group type: COMPARATOR
Intervention: Lovastatin IR
Number of subjects: 76
Study: 9437308

Group type: EXPERIMENTAL
Intervention: Intracapsular cataract extraction with aphakic glasses (ICCE‐AG)
Number of subjects: 3400

Group type: COMPARATOR
Intervention: Extracapsular cataract extraction with posterior chamber intraocular lens (ECCE/PC-IOL)
Number of subjects: 3400
Study: 8620672

Group type: EXPERIMENTAL
Intervention: Zileuton 600mg with food
Number of subjects: 18

Group type: COMPARATOR
Intervention: Zileuton 600mg without food
Number of subjects: 18
Study: 2672652

Group type: EXPERIMENTAL
Intervention: 120 mg isosorbide dinitrate s.r. (slow release)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 892377

Group type: EXPERIMENTAL
Intervention: 10% peptone perfusion at 2 ml per min for 4 hr
Number of subjects: 14

Group type: COMPARATOR
Intervention: 0.2 M NaCl perfusion at 2 ml per min for 4 hr (Control)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pentagastrin 6 μg/kg subcutaneously
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Duodenal peptone perfusion
Number of subjects: 14
Study: 4869880

Group type: EXPERIMENTAL
Intervention: Two new sedatives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard barbiturate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 0
Study: 31810220

Group type: EXPERIMENTAL
Intervention: Problem solving based psychoeducational group intervention (PE)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nonstructured group (NS)
Number of subjects: 22
Study: 30496464

Group type: EXPERIMENTAL
Intervention: Ethambutol arm
Number of subjects: 1932

Group type: EXPERIMENTAL
Intervention: Isoniazid arm
Number of subjects: 1932
Study: 26695353

Group type: EXPERIMENTAL
Intervention: Barbell hip thrust
Number of subjects: 13

Group type: COMPARATOR
Intervention: American hip thrust
Number of subjects: 13

Group type: COMPARATOR
Intervention: Band hip thrust
Number of subjects: 13
Study: 25205361

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPD) at a dosage of 0.5 to 0.8 mg/kg/d
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 22192670

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/d for 3 days before surgery
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Atorvastatin (ex vivo)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 303
Study: 20658483

Group type: EXPERIMENTAL
Intervention: Lactobacillus gasseri A5 (n = 49)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo (n = 56)
Number of subjects: 105
Study: 17187610

Group type: EXPERIMENTAL
Intervention: Omeprazole + Amoxicillin-Clarithromycin (OAC)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Amoxicillin-Clarithromycin (AC)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both OAC and AC regimens
Number of subjects: 46
Study: 15203997

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% cream
Number of subjects: 173

Group type: COMPARATOR
Intervention: Tretinoin 0.05% emollient cream
Number of subjects: 173
Study: 11599659

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 150 IU/kg s.c. three times weekly (t.i.w.)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Epoetin alfa 40,000 IU s.c. once weekly (q.w.)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both regimens (t.i.w. and q.w.)
Number of subjects: 36
Study: 9836024

Group type: EXPERIMENTAL
Intervention: d-amphetamine (0.25 mg/kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 8137476

Group type: EXPERIMENTAL
Intervention: 5‐Fluorouracil (5‐FU) at 330 mg/m2 per week, Adriamycin (ADR) at 20 mg/m2 every 4 weeks, and mitomycin C (MMC) at 2.7 mg/m2 every 2 weeks
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 5‐Fluorouracil (5‐FU) at 330 mg/m2 per week and epirubicin (EPIR) at 20 mg/m2 every 2 weeks
Number of subjects: 56
Study: 2912533

Group type: EXPERIMENTAL
Intervention: Metoclopramide and lorazepam
Number of subjects: 64

Group type: COMPARATOR
Intervention: Metoclopramide alone
Number of subjects: 64
Study: 1202613

Group type: EXPERIMENTAL
Intervention: Trimipramine (50 mg tablets, perorally, 3 hours before test)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Histalog (1 mg per kg body weight, intramuscular injection)
Number of subjects: 10
Study: 29453769

Group type: EXPERIMENTAL
Intervention: HPV testing (genotyping)
Number of subjects: 2255

Group type: EXPERIMENTAL
Intervention: HPV33
Number of subjects: 2255

Group type: EXPERIMENTAL
Intervention: HPV16
Number of subjects: 2255

Group type: EXPERIMENTAL
Intervention: HPV35
Number of subjects: 2255

Group type: EXPERIMENTAL
Intervention: Group A (HPV types 33, 16, 35)
Number of subjects: 2255

Group type: EXPERIMENTAL
Intervention: Group A or B (HPV types 31, 52, 18, 59, 58)
Number of subjects: 2255

Group type: EXPERIMENTAL
Intervention: Group A or B or C (HPV types 39, 51, 56, 45, 68)
Number of subjects: 2255

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 2255

Group type: EXPERIMENTAL
Intervention: Group B
Number of subjects: 2255

Group type: EXPERIMENTAL
Intervention: Group C
Number of subjects: 2255
Study: 28963278

Group type: EXPERIMENTAL
Intervention: GoActive intervention
Number of subjects: 2400
Study: 26645928

Group type: EXPERIMENTAL
Intervention: Usual care + video messaging
Number of subjects: 912

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 912
Study: 24284080

Group type: EXPERIMENTAL
Intervention: Speech and images (group 2)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Speech, images, and image annotation (group 3)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Speech only (group 1)
Number of subjects: 42
Study: 21116186

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (specific details not provided)
Number of subjects: 603
Study: 18607309

Group type: COMPARATOR
Intervention: No ARV use
Number of subjects: 93

Group type: COMPARATOR
Intervention: Unprotected sexual intercourse
Number of subjects: 93

Group type: COMPARATOR
Intervention: Viral load >1000 copies/mL
Number of subjects: 93

Group type: COMPARATOR
Intervention: Median viral loads
Number of subjects: 93

Group type: COMPARATOR
Intervention: ARV use
Number of subjects: 93
Study: 17167159

Group type: EXPERIMENTAL
Intervention: Tai Chi Chih (TCC) for 20 minutes
Number of subjects: 32

Group type: COMPARATOR
Intervention: Passive rest (control group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Slow-moving physical activity (videotape-guided stretching for 20 minutes)
Number of subjects: 32
Study: 12585099

Group type: EXPERIMENTAL
Intervention: Tripterygiitotorum (T II) plus prednisone
Number of subjects: 68

Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 68
Study: 10612483

Group type: EXPERIMENTAL
Intervention: Cetrorelix (10 mg daily subcutaneous injections for five days and 60 mg depot)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cetrorelix (10 mg daily intramuscular injections for five days and placebo depot)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (daily and depot injections)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cetrorelix (pooled data from groups C + C and C + P)
Number of subjects: 10
Study: 7742423

Group type: EXPERIMENTAL
Intervention: Dapsone/pyrimethamine (200/75 mg once weekly)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Aerosolized pentamidine (300 mg once every 4 weeks)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Dapsone/pyrimethamine
Number of subjects: 501
Study: 2184183

Group type: EXPERIMENTAL
Intervention: Echocardiography (two-dimensional and Doppler)
Number of subjects: 70
Study: 6998284

Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Glucagon and Placebo
Number of subjects: 22
Study: 31634023

Group type: EXPERIMENTAL
Intervention: Wixela Inhub (FP/salmeterol 100/50 μg)
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Advair Diskus (FP/salmeterol 100/50 μg)
Number of subjects: 1127
Study: 29351117

Group type: EXPERIMENTAL
Intervention: Subjects with comorbid anxiety disorders
Number of subjects: 178

Group type: COMPARATOR
Intervention: Subjects without comorbid anxiety disorders
Number of subjects: 178
Study: 28267249

Group type: COMPARATOR
Intervention: ASA 81 mg once-daily
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: ASA 162 mg twice-daily
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: ASA 325 mg once-daily
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: ASA 162 mg twice-daily or 81 mg four times daily (pooled data)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: ASA 325 mg once-daily (pooled data)
Number of subjects: 68
Study: 26528651

Group type: EXPERIMENTAL
Intervention: Stage-based smoking cessation services
Number of subjects: 223

Group type: COMPARATOR
Intervention: Usual aftercare
Number of subjects: 223
Study: 23924680

Group type: EXPERIMENTAL
Intervention: Posaconazole
Number of subjects: 252

Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 252
Study: 20880870

Group type: EXPERIMENTAL
Intervention: Cylinder oxygen provided at 6 l/min intranasally during activities provoking breathlessness
Number of subjects: 143

Group type: COMPARATOR
Intervention: Cylinder air provided at 6 l/min intranasally during activities provoking breathlessness
Number of subjects: 143
Study: 18465129

Group type: EXPERIMENTAL
Intervention: (18)F fluoride PET-CT
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: (18)F FCH PET-CT
Number of subjects: 38
Study: 16796502

Group type: EXPERIMENTAL
Intervention: Videoconference telepsychiatry (VCTP) treatment
Number of subjects: 140

Group type: COMPARATOR
Intervention: Face-to-face conventional (F2FC) treatment
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both VCTP and F2FC treatments
Number of subjects: 140
Study: 12752071

Group type: EXPERIMENTAL
Intervention: Intrauterine progestogens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antifibrinolytic agents (tranexamic acid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory agents (mefenamic acid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endometrial destructive techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fibroid embolization
Number of subjects: 0
Study: 10739510

Group type: EXPERIMENTAL
Intervention: 3-keto-desogestrel (1.5, 3, or 6 microg daily)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control (0 microg of 3-keto-desogestrel)
Number of subjects: 203
Study: 9209517

Group type: EXPERIMENTAL
Intervention: Preoperative intraluminal brachytherapy (IBT) - moderate-dose group (16-40 Gy; n = 96)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Preoperative intraluminal brachytherapy (IBT) - high-dose group (40-80 Gy; n = 19)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (no radiation prior to radical surgery; n = 115)
Number of subjects: 115
Study: 8130430

Group type: EXPERIMENTAL
Intervention: Simultaneous swim-up/swim-down procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Discontinuous Percoll gradient centrifugation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Swim-up method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Swim-down sperm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Swim-up/swim-down procedure
Number of subjects: 0
Study: 3312501

Group type: EXPERIMENTAL
Intervention: Dilevalol 200-800 mg/day
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 29845573

Group type: EXPERIMENTAL
Intervention: Ischemic Conditioning (IC)
Number of subjects: 207

Group type: COMPARATOR
Intervention: No Ischemic Conditioning (NIC)
Number of subjects: 207
Study: 27556593

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 24618385

Group type: EXPERIMENTAL
Intervention: ATG-F 9 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22409587

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES) for bifurcation lesions
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 814
Study: 20868907

Group type: EXPERIMENTAL
Intervention: Droperidol (10 mg)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Midazolam (10 mg)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Droperidol (5 mg) / Midazolam (5 mg)
Number of subjects: 91
Study: 18942250

Group type: EXPERIMENTAL
Intervention: Epidural ketamine 40 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epidural morphine 2 mg
Number of subjects: 0